Search

Displaying results 2161 - 2170 of 7604 in total
  1. Drug

    Lactitol

    go.drugbank.com/drugs/DB12942
    Approved

    [A190915,A190918] Pizensy, an oral lactitol powder for solution, was approved by the FDA for use in chronic idiopathic constipation in February 2020.[L11803] … [A190912] Clinically, lactitol has been investigated for use as an osmotic laxative and, along with other non-absorbable disaccharides such as [lactulose], in the treatment of hepatic encephalopathy in

    Categories: Drugs for Constipation, Compounds used in a research, industrial, or household setting
  2. Drug

    Piflufolastat F 18

    go.drugbank.com/drugs/DB14805
    ApprovedInvestigational

    [A235169] As such, it has become a desirable target for PET imaging of prostate cancer tissues. … [L34324] On July 28, 2023, the EMA also approved Piflufolastat F18 under the brand name PYLCLARI for primary staging or localizing recurrence of prostate cancer.[L47586]

  3. Drug

    Azimilide

    go.drugbank.com/drugs/DB04957
    Investigational

    It is not approved for use in any country, but is currently in clinical trials in the United States.

  4. Drug

    Istradefylline

    go.drugbank.com/drugs/DB11757
    ApprovedInvestigational

    Istradefylline, or KW6002, was developed by Kyowa Hakko Kirin in Japan for the treatment of Parkinson's disease as an adjunct to standard therapy. … [A184067] Unlike standard dopaminergic therapies for Parkinson's, Istradefylline targets adenosine A<sub>2A</sub> receptors in the basal ganglia.

  5. Drug

    Vonoprazan

    go.drugbank.com/drugs/DB11739
    ApprovedInvestigational

    PCABs represent an alternative to proton-pump inhibitors for the treatment of acid-related disorders. … [A253702] In May 2022, the FDA approved the use of vonoprazan in a co-packaged product containing amoxicillin and clarithromycin for the treatment of _H. pylori_ infection.

    Categories: Drugs for Acid Related Disorders, Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)
  6. Drug

    Repotrectinib

    go.drugbank.com/drugs/DB16826
    ApprovedInvestigational

    [A262066] On November 15th, 2023, the FDA approved repotrectinib under the brand name Augtyro for the treatment of locally advanced or metastatic ROS1-Positive NSCLC. … [A262056] ROS1 mutations are one of the defined oncogenic drives of NSCLC, and the solvent-front mutation ROS1 G2032R is responsible for 50 to 60% of [crizotinib]-resistant cases.

  7. Drug

    Equine Botulinum Neurotoxin A Immune FAB2

    go.drugbank.com/drugs/DB13900
    Approved

    It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes A in adults and pediatric patients.

  8. Drug

    Metandienone

    go.drugbank.com/drugs/DB13586
    ApprovedWithdrawn

    [A254432] In the US, metandienone is a controlled substance under the Controlled Substances Act.[L44057]

    Categories: Androgens for Topical Use, Anabolic Agents for Systemic Use
  9. Drug

    Desvenlafaxine

    go.drugbank.com/drugs/DB06700
    ApprovedInvestigational

    [A261266,A261266] It was approved by the FDA in 2008 for the treatment of adults with major depressive disorder (MDD). … The major difference is the potential for drug interaction since venlafaxine is mainly metabolized by CYP2D6 while desvenlafaxine is conjugated by UGT; therefore, desvenlafaxine is less likely to cause

    Categories: Antidepressive Agents Indicated for Depression
  10. Drug

    Nitrous acid

    go.drugbank.com/drugs/DB09112
    ApprovedInvestigational

    There is also research to investigate its applicability towards treatments for heart attacks, brain aneurysms, pulmonary hypertension in infants, and Pseudomonas aeruginosa infections.

    Categories: Compounds used in a research, industrial, or household setting